亚胺培南西司他丁钠美罗培南在重症肺部感染患者治疗效果及成本分析

doi:10.3969/j.issn.1006-6233.2020.12.035

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1248 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的: 分析重症肺部感染患者临床症状,依照个案实际情况给予亚胺培南西司他丁钠、美罗培南治疗,探讨该方案的最终效果并计算治疗成本。方法: 选取2017年1月至2019年12月我院收治的80例重症肺部感染患者作为研究对象,红蓝球分组法将其分为两组,亚胺培南西司他丁钠组患者行亚胺培南西司他丁钠治疗,美罗培南组患者行美罗培南治疗。对比两组干预效果、血气水平、炎性指标、治疗成本。结果: 两组患者的干预效果并无明显差异(80.0%VS85.0%)(P＞0.05);亚胺培南西司他丁钠组患者血气PaO₂、PCO₂、PaO₂/FiO₂、PCT、CRP水平优于美罗培南组,差异具有统计学意义(P<0.05);亚胺培南西司他丁钠组治疗成本-效果优异于美罗培南组,差异具有统计学意义(P<0.05)。结论: 亚胺培南西司他丁钠与美罗培南均对重症肺部感染的治疗均具有积极意义。但亚胺培南西司他丁钠在改善患者血气水平、炎性反应等方面效果更佳,与美罗培南组对比,亚胺培南西司他丁钠组治疗成本-效果更佳,有明显的药物经济学优势。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	熊果
	吴秀芹
	黄琼秀
	李小露

关键词 ：重症肺部感染, 亚胺培南西司他丁钠, 美罗培南, 效果, 治疗成本

Abstract：Objective: To analyze the clinical symptoms of patients with severe pulmonary infection, and to give imipenem cilastatin sodium and meropenem treatment according to the actual situation of the case, explore the final effect of the program and calculate the treatment cost. Methods: 80 patients with severe pulmonary infection admitted to our hospital from January 2017 to December 2019 were selected as the study subjects. They were divided into two groups by the red-and-blue grouping method. Patients in group A were treated with imipenem xastatin sodium, and patients in group B were treated with meropenem. The intervention effect, blood gas level, inflammatory index, bacteria culture result, drug susceptibility test result and treatment cost were compared. Results: There was no significant difference in intervention effect between group A and group B (80.0%VS85.0%) (P>, 0.05). Before intervention, there was no significant difference in blood gas index and inflammatory index between the two groups (P>0.05). After intervention, the blood gas levels of group A, PaO₂, PCO₂, PaO₂/FiO₂, PCT and CRP were all better than those of group B, with statistically significant difference (P<0.05). After treatment, the bacteria culture of group B was lower than that of group A (P<0.05). The cost-effectiveness of treatment in group B was significantly lower than that in group A (P<0.05). Conclusion: Both imipenem and cilastatin sodium and meropenem are of positive significance in the treatment of severe pulmonary infection. Meropenem is better than imipenem and cilastatin sodium in improving patients' blood gas level, immunity, and pathogen removal, reducing the treatment effect-cost, and its clinical application value is better than imipenem cilastatin sodium.

Key words： Severe pulmonary infection Imipenem and cilastatin sodium Meropenem Effect Treatment cost

基金资助:广东省科技厅项目,(编号:[2017]137号-129)

引用本文:

熊果, 吴秀芹, 黄琼秀, 李小露. 亚胺培南西司他丁钠美罗培南在重症肺部感染患者治疗效果及成本分析[J]. 河北医学, 2020, 26(12): 2083-2086.
XIONG Guo, WU Xiuqin, HUANG Qiongxiu, et al. Analysis of Treatment Effect and Cost of Imipenem Cilastatin Sodium and Meropenem in Patients with Severe Pulmonary Infection. HeBei Med, 2020, 26(12): 2083-2086.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2020.12.035 或 http://www.hbyxzzs.cn/CN/Y2020/V26/I12/2083